F10 and hemophilia: The catalytic efficiency (kcat/Km) by which FVIIIa enhances activated factor X (FXa) generation is 10 times higher than that of emicizumab while patients under prophylactic treatment with emicizumab show annualized bleeding rates and hemostatic potentials close to that of patients with moderate hemophilia [14, 15].